HER2 Support Group Forums - View Single Post - Mammaglobin-A DNA vaccine

AmyE · 11-17-2011, 01:28 PM

Hello-
I'm waiting to hear if I meet the requirements, have passed one of them.
Have any of you heard of this? a short phase 1 trial. My oncologist thinks it will boost my immunity, although they state no medical benefits in the information sheet given to me. Link below, I appreciate any information!
(A bit nervous since this is a Phase 1)
thanks,
Amy
they are okay with me getting the Herceptin every 3 weeks, which I am.
I also take Arimidex daily, Xgeva every 6 weeks.
I am HER2+, ER+, PR+

This is a phase I open-label study to evaluate the safety and immunogenicity of a plasmid mammaglobin-A DNA vaccine. The plasmid mammaglobin-A DNA vaccine will be formulated as a naked plasmid DNA vaccine (WUSM-MGBA-01). The hypothesis of this study is that the mammaglobin-A DNA vaccine will be safe for human administration and capable of generating measurable CD8 T cell responses to mammaglobin-A. The primary objective of this study is to demonstrate the safety of the mammaglobin-A DNA vaccine. The secondary objective is to evaluate the immunogenicity of the mammaglobin-A DNA vaccine as measured by ELISPOT analysis, a surrogate for CD8 T cell function.

http://www.clinicalconnection.com/ex...05&slID=667230

11-17-2011, 01:28 PM	#1
AmyE Member Join Date: Apr 2011 Posts: 8	Mammaglobin-A DNA vaccine Hello- I'm waiting to hear if I meet the requirements, have passed one of them. Have any of you heard of this? a short phase 1 trial. My oncologist thinks it will boost my immunity, although they state no medical benefits in the information sheet given to me. Link below, I appreciate any information! (A bit nervous since this is a Phase 1) thanks, Amy they are okay with me getting the Herceptin every 3 weeks, which I am. I also take Arimidex daily, Xgeva every 6 weeks. I am HER2+, ER+, PR+ This is a phase I open-label study to evaluate the safety and immunogenicity of a plasmid mammaglobin-A DNA vaccine. The plasmid mammaglobin-A DNA vaccine will be formulated as a naked plasmid DNA vaccine (WUSM-MGBA-01). The hypothesis of this study is that the mammaglobin-A DNA vaccine will be safe for human administration and capable of generating measurable CD8 T cell responses to mammaglobin-A. The primary objective of this study is to demonstrate the safety of the mammaglobin-A DNA vaccine. The secondary objective is to evaluate the immunogenicity of the mammaglobin-A DNA vaccine as measured by ELISPOT analysis, a surrogate for CD8 T cell function. http://www.clinicalconnection.com/ex...05&slID=667230